Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Head and Neck Squamous Cell Carcinoma (HNSCC) patients urgently need improved therapies to prevent tumor relapses.
• This study investigates the role of Rac1, a Rho GTPase, in HNSCC chemo-radiotherapy resistance and recurrence.

Purpose of the Study:

• To determine if Rac1 is involved in HNSCC treatment resistance and recurrence.
• To evaluate the potential of Rac1 inhibition as a therapeutic strategy for HNSCC.

Main Methods:

• Utilized parental and radiation-resistant HNSCC cell lines to assess sensitivity to radiation and cisplatin.
• Analyzed Rac1 activity, expression, and localization in cells and in tumor tissues from 60 HNSCC patients.

Main Results:

• Radiation-resistant cells showed increased Rac1 activity, expression, and nuclear translocation, correlating with cisplatin resistance.
• Inhibiting Rac1 enhanced HNSCC sensitivity to chemo-radiotherapy.
• Elevated Rac1 expression, particularly in the nucleus, was observed in patient tumors with poor treatment response and recurrence.

Conclusions:

• Increased Rac1 expression, activity, and nuclear localization are associated with poor treatment response and higher recurrence risk in HNSCC.
• Rac1 inhibition shows promise for overcoming chemo-radiotherapy resistance in HNSCC patients, potentially reducing tumor recurrence.